Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

Pneumonia III: Complications and Assessment

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

Pneumonia V: Nursing management and Prevention

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.

Atypical Pneumonia

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The ARDS, Pneumonia, and Sepsis (APS) Consortium: Rationale, Design, and Feasibility of a National Platform for Phenotyping Critical Illness Syndromes.

Chest·2026

Same author

Comparing risk factors in severe COVID-19 using machine learning and non-machine learning methods: analysis from 2 international randomized controlled trials.

JAMIA open·2026

Same author

The Role of Complex Digital Interventions to Improve Pneumonia Care.

Clinics in chest medicine·2026

Same author

Prognostic Value of Lung Injury Biomarkers in Patients Hospitalized With COVID-19 Without Respiratory Failure at Admission.

Critical care medicine·2026

Same author

User-Centered Redesign of a Clinical Decision Support System for Pneumonia in the Emergency Department.

Applied clinical informatics·2026

Same author

The Long-term Pneumonia Mortality Index: an international multicenter derivation and validation study for patients with community-acquired pneumonia.

American journal of respiratory and critical care medicine·2026

Search research articles

Related Experiment Videos

Defining and predicting severe community-acquired pneumonia.

Samuel M Brown¹, Nathan C Dean

¹Division of Pulmonary and Critical Care Medicine, Intermountain Medical Center, University of Utah, Salt Lake City, Utah, USA. Samuel.Brown@imail.org

Current Opinion in Infectious Diseases

|January 7, 2010

Summary

Predicting severe community-acquired pneumonia is crucial. Recent models like the Infectious Disease Society of America/American Thoracic Society guidelines and SMART-COP show promise, outperforming older methods.

Keywords:

Biomarkers Community-Acquired Pneumonia Prognostic Models Severity Assessment

Related Experiment Videos

Area of Science:

Pulmonary Medicine
Infectious Diseases
Public Health

Background:

Community-acquired pneumonia presents a significant challenge in clinical practice and public health.
Accurate assessment of pneumonia severity is difficult yet critical for patient management and resource allocation.

Purpose of the Study:

To review recent advancements in defining and predicting the severity of community-acquired pneumonia.
To evaluate the utility of novel predictive models and biomarkers for pneumonia severity.

Main Methods:

Review of recently proposed predictive models for pneumonia severity.
Validation of these models in diverse patient cohorts.
Assessment of the role of biomarkers in pneumonia severity prediction.

Main Results:

Several new predictive models and advanced methods for assessing pneumonia severity have been introduced and validated.
The Infectious Disease Society of America/American Thoracic Society 2007 guidelines and the SMART-COP model are identified as promising for predicting severe pneumonia at presentation.
Traditional models like the Pneumonia Severity Index and CURB-65 are considered less useful.
Biomarkers show potential but lack validated roles in current pneumonia severity assessment.

Conclusions:

The definition of pneumonia severity should align with specific clinical or public health objectives, with a health services reference definition being broadly applicable.
The Infectious Disease Society of America/American Thoracic Society 2007 guidelines and SMART-COP offer improved prediction of severe pneumonia compared to older models.
Accurate severity assessment is vital for patient triage, outcome prediction, and research cohort definition.
Novel biomarkers require further validation before clinical integration into pneumonia severity assessment.